Metallo-Drugs: Development and Action of Anticancer Agents
Ed. by Sigel, Astrid / Sigel, Helmut / Freisinger, Eva / Sigel, Roland K.O.
With contrib. by Riddell, Imogen / Lippard, Stephen J. / Brabec, Victor / Kasparkova, Jana / Menon, Vijay / Farrell, Nicholas P. / Venkatesh, V. / Sadler, Peter J. / Gorle, Anil K. / Peterson, Erica J. / Berners-Price, Susan / Alessio, Enzo / Messori, Luigi / Babak, Maria V. / Ang, Wee Han / Casini, Angela / Sun, Raymond Wai-Yin / Ott, Ingo / Tshuva, Edit / Miller, Maya / Crans, Debbie / Yan, Lining / Haase, Allison / Yang, Xiaogai / Chitambar, Christopher / Cardo, Lucia / Hannon, Michael John / Vilar, Ramon / Sullivan, Matthew P. / Holtkamp, Hannah U. / Hartinger, Christian G. / Schatzschneider, Ulrich / Thévenod, Frank / Denoyer, Delphine / Clatworthy, Sharnel A. S. / Cater, Michael / Ziliotto, Silvia / Ogle, Olivia / Taylor, Kathryn M.
Series:Metal Ions in Life Sciences 18
- eBook (PDF)
- Publication Date:
- February 2018
- Copyright year:
13. Antitumor Metallodrugs that Target Proteins
Sullivan, Matthew P. / Holtkamp, Hannah U. / Hartinger, Christian G.
Anticancer platinum-based drugs are widely used in the treatment of a variety of tumorigenic diseases. They have been identified to target DNA and thereby induce apoptosis in cancer cells. Their reactivity to biomolecules other than DNA has often been associated with side effects that many cancer patients experience during chemotherapy. The development of metal compounds that target proteins rather than DNA has the potential to overcome or at least reduce the disadvantages of commonly used chemotherapeutics. Many exciting new metal complexes with novel modes of action have been reported and their anticancer activity was linked to selective protein interaction that may lead to improved accumulation in the tumor, higher selectivity and/or enhanced antiproliferative efficacy. The development of new lead structures requires bioanalytical methods to confirm the hypothesized modes of action or identify new, previously unexplored biological targets and pathways. We have selected original developments for review in this chapter and highlighted compounds on track toward clinical application.
Matthew P. Sullivan, Hannah U. Holtkamp, Christian G. Hartinger (2018). 13. Antitumor Metallodrugs that Target Proteins. In Astrid Sigel, Helmut Sigel, Eva Freisinger, Roland K.O. Sigel (Eds.), Metallo-Drugs: Development and Action of Anticancer Agents (pp. 351–386). Berlin, Boston: De Gruyter. https://doi.org/10.1515/9783110470734-019
Book DOI: https://doi.org/10.1515/9783110470734
Online ISBN: 9783110470734© 2018 Walter de Gruyter GmbH, Berlin/Munich/Boston